Rare Cancer Drug Cuts Death Risk by 45% in Trial

A new treatment for a deadly soft-tissue cancer has delivered breakthrough results, extending survival by over eight months compared to placebo.

For patients with advanced dedifferentiated liposarcoma, this marks the first effective targeted therapy ever proven in a major trial.